Research site

Messina 98158

1 studies enrolling now · 30 studies all time

What they study most

ATTR Amyloidosis, Adenocarcinoma of the Pancreas, Advanced ER-Positive HER2-Negative Breast Cancer, Advanced Malignancy, Advanced Solid Tumors, Advanced or Metastatic Breast Cancer, Anemia, Asthma, Bone Metastases, Breast Cancer, COPD, Cancer

Studies at this site

• OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis — Recruiting now
• Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. — Running, not enrolling
• A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) — Running, not enrolling
• To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. — Running, not enrolling
• A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer — Running, not enrolling
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) — Running, not enrolling
• Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations — Running, not enrolling
• Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer — Running, not enrolling
• Study of ALXN2220 Versus Placebo in Adults With ATTR-CM — Running, not enrolling
• A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia — Stopped early
• Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis — Stopped early
• Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy — Completed
• Observational Study of Obstructive Lung Disease (NOVELTY) — Completed
• QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas — Completed
• Dimethyl Fumarate (DMF) Observational Study — Completed
• Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy — Stopped early
• Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma — Completed
• Plegridy Observational Program — Completed
• Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments — Completed
• Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) — Stopped early
• Safety Study of Entocort for Children With Crohn's Disease — Completed
• Safety and Maintenance Study of Entocort for Children With Crohn's Disease — Completed
• Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer — Completed
• Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) — Completed
• A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma — Completed
• Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis — Completed
• T790M Mutation Positive 2nd Line STandard of cAre Registry — Withdrawn before enrolling
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer — Stopped early
• GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes — Stopped early
• G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study) — Stopped early